Childhood inattentive ADHD symptoms are associated with adverse occupational outcomes and higher stress levels in adulthood.

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced ...

Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.

Viloxazine extended-release shows promise for treating adults with ADHD who also experience symptoms of depression and anxiety.

Otsuka Pharma announces positive phase 3b results for centanafadine in adults with ADHD and comorbid anxiety: Tokyo, Japan Friday, June 26, 2026, 17:00 Hrs [IST] Otsuka Pharmaceut ...

This study examined the brain networks related to hyperactivity and impulsivity in children with Attention-Deficit/Hyperactivity Disorder (ADHD) and aimed to develop ...

aDepartment of Psychiatry and Behavioral Health, Center for Children and Families, Florida International University, Miami, FL, USA bDepartment of Psychiatry and Behavioral Sciences, Duke University ...

A phase 3b trial of Otsuka’s attention-deficit/hyperactivity disorder (ADHD) prospect has hit its primary endpoint, strengthening the drugmaker’s hand weeks ...

Otsuka Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced positive topline results in a phase 3b study evaluating centanafadine XR 280 mg once ...

FOCUS-3 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of ...